Estuary Biotherapeutics announced its launch on 16 October with $103 million in total committed financing to develop gene therapies for inherited kidney disease. The total includes a $93 million Series A led by RA Capital Management and an earlier $10 million seed round co-led by 4BIO Capital and GV. The company announcement says the money will support two experimental programmes through clinical proof of concept and further development of its kidney-targeting technology.
The company expects EST-201, aimed at disease associated with PKD2 mutations, to enter clinical testing in 2027. EST-101, for patients with PKD1 mutations, is expected to follow in 2028. Those are development targets. The programmes address autosomal dominant polycystic kidney disease, known as ADPKD. The announcement identifies Yale researchers Stefan Somlo and Michael Caplan as scientific co-founders.
What the financing documents show
A separate Form D filed with the US Securities and Exchange Commission on 16 October records an equity offering of $103,654,385. It lists $40,654,685 as sold and $62,999,700 remaining to be sold, with 25 investors already participating. The filing gives 1 July 2026 as the date of the first sale and identifies the company as incorporated in Delaware in 2022. Its public launch therefore does not mark the beginning of its corporate existence.
The announcement uses committed financing, while the filing reports securities sold in the offering. These measures should not be treated as interchangeable. Neither document provides a reconciliation of the two presentations or a schedule for receiving the remaining funding. The SEC notice also states that the regulator has not necessarily reviewed its contents or determined that they are accurate and complete.
Estuary’s published pipeline explains how the two programmes differ. EST-201 carries a full-length PKD2 gene using an adeno-associated virus, or AAV. EST-101 instead carries a functional region derived from the polycystin-1 protein. The company says that smaller sequence can be packaged into AAV, whereas full-length PKD1 cannot. The proposal is to restore a missing biological function through gene addition.
The company describes a delivery method intended to reach target cells directly within the kidney. It says the programmes share a delivery route, target cell type and AAV capsid. Its pipeline also lists EST-102, another PKD1 programme, and possible work on other kidney diseases. These descriptions explain the research platform; they do not establish that it is safe or effective in patients.
What the mouse research establishes
The scientific background includes a Yale School of Medicine report from 12 October 2021 on work led by Stefan Somlo. Researchers engineered mice so that PKD2 could be switched off and later switched back on. After reactivation, kidney size decreased, cysts resolved and kidney tubules recovered their usual form. The team used repeated MRI scans to follow the changes and repeated the experiment with PKD1, with similar findings.
That work also identified a limit relevant to claims about reversing disease. In later-stage disease in the mice, kidney size and inflammation improved, but scarring could no longer be fully repaired. The result supports investigation of whether restoring polycystin proteins can alter disease biology. It does not show that an experimental medicine can reverse all kidney damage in people, particularly after substantial scarring has developed.
A second Yale account, dated 30 March 2023, describes research led by Laura Onuchic and Michael Caplan on the size problem facing PKD1 gene delivery. Their experiments found that a fragment containing 200 amino acids from the end of the polycystin-1 protein could suppress cystic disease in genetically modified mice. The fragment is much smaller than the full protein, which the researchers described as too large for conventional gene-delivery vehicles.
The researchers also identified an interaction between that fragment and the mitochondrial protein nicotinamide nucleotide transhydrogenase. This supplied a lead for investigating how the fragment works, alongside the observation of smaller cysts. The university described further gene-therapy work in mouse models as the next research step at the time. These are earlier laboratory findings underpinning the approach, not clinical results newly announced with the financing.
Estuary’s website explicitly says its investigational programmes have not been approved by the FDA or any other regulatory authority, and that safety and efficacy have not been established.
Dalimss News has separately covered Microbiotica’s financing for a next-stage trial and OMass Therapeutics’ funding for drug trials.
